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Abstract
Objective—To develop a risk score to identify women with vesicovaginal fistula at high risk of 
residual urinary incontinence after surgical repair.
Methods—We conducted a prospective cohort study among 401 women undergoing their first 
vesicovaginal fistula repair at a referral fistula repair center in Lilongwe, Malawi, between 
September 2011 and December 2014, who returned for follow-up within 120 days of surgery. We 
used logistic regression to develop a risk score to identify women with high likelihood of residual 
urinary incontinence, defined as incontinence grade 2-5 within 120 days of vesicovaginal fistula 
repair, based on preoperative clinical and demographic characteristics (age, number of years with 
fistula, HIV status, body mass index, previous repair surgery at an outside facility, revised Goh 
Classification, Goh vesicovaginal fistula size, circumferential fistula, vaginal scaring, bladder size, 
and urethral length). The sensitivity, specificity, positive and negative predictive values of the risk 
score at each cut-point were assessed.
Results—Overall, 11 (3%) women had unsuccessful fistula closure. Of those with successful 
fistula closure (n=372), 85 (23%) experienced residual incontinence. A risk score cut-point of 20 
had sensitivity 82% (95% CI 72%, 89%) and specificity 63% (95% CI 57%, 69%) to potentially 
identify women with residual incontinence. In our population, the positive predictive value for a 
risk score cut-point of _20 or higher was 43% (95% CI 36%, 51%) and the negative predictive 
value was 91% (95% CI 86%, 94%). Forty-eight percent of our study population had a risk score 
≥20 and therefore, would have been identified for further intervention.
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Conclusions—A risk score 20 or higher was associated with an increased likelihood of residual 
incontinence, with satisfactory sensitivity and specificity. If validated in alternative settings, the 
risk score could be used to refer women with high likelihood of postoperative incontinence to 
more experienced surgeons.
Introduction
Obstetric fistula is a debilitating condition that affects an estimated 1-2 million women 
globally.(1, 2) Vesicovaginal fistula is an abnormal communication between the bladder and 
vagina, which typically occurs as a result of prolonged obstructed labor during childbirth.(3) 
Vesicovaginal fistula leaves women incontinent of urine and has devastating physical and 
emotional consequences.(4)
Surgical repair remains the primary treatment for vesicovaginal fistula. Successful surgical 
repair is defined anatomically as closing the fistula and functionally as the absence of 
urinary and/or fecal incontinence after surgery.(5-7) Surgical success based on anatomical 
closure varies from 80%-95%.(5) However, up to 20% (8) of women with successful fistula 
closure continue to suffer from residual urinary incontinence after surgery. Overall, between 
5% (9) and nearly 40% of women experience residual incontinence after surgery.(10) Given 
the devastating consequences of residual incontinence for women's health and quality of life, 
a greater understanding of prognostic factors for residual urinary incontinence is needed.(11)
The objective of our study was to develop a risk score to identify women with vesicovaginal 
fistula at high risk of residual urinary incontinence after surgical repair. The risk score could 
be used by physicians prior to surgery to identify cases which may benefit from referral to a 
more experienced surgeon or additional intervention to increase the likelihood of post-
operative continence. Determining a risk score cut-point which could be used to identify 
women at high risk of residual incontinence may lead to more efficient use of healthcare 
resources, and ultimately improved surgical outcomes for women with vesicovaginal fistula.
Materials and Methods
We conducted a cohort study of women seeking surgical repair for vesicovaginal fistula at 
the Freedom from Fistula Care Centre at Bwaila Hospital in Lilongwe, Malawi. Women are 
referred to the Fistula Centre from throughout Malawi, western Mozambique, and eastern 
Zambia. Referred patients undergo a comprehensive clinical history and physical 
examination upon admission to the Fistula Care Centre. In addition, all women complete a 
30-minute survey with detailed demographic, obstetric, and reproductive information upon 
admission. Surveys were conducted in either the local language (Chichewa) or English by 
staff members trained in data collection.
Prior to surgery, all patients were screened for HIV infection, underwent a physical 
examination and nutritional assessment, and fistula staging was documented. Fitness for 
surgery was determined by the head fistula surgeon. Women who test positive for HIV had 
their CD4 count evaluated and initiated combinational antiretroviral therapy treatment in 
accordance with national HIV treatment guidelines.(12) After starting HIV treatment, 
women were re-evaluated after 3-6 months to determine fitness for surgery. Women with 
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poor nutrition, based on weight and mean upper arm circumference, were given nutritional 
supplementation preoperatively whenever possible and surgery was delayed until their 
nutrition status improved. All patients received a dose of prophylactic antibiotics prior to 
surgery.
Fistula cases referred to the Fistula Care Centre are often complex and damage that involves 
the bladder neck and proximal urethra is common. Women with fistulas that involve the 
urethral closure mechanism are at high risk of post-operative urinary incontinence.(8) To 
help improve the changes of regaining continence after surgery a pubococcygeal sling or 
other sling-like techniques (13) are used in all women with a short urethra (approximately 
≤2 cm) as a preventative measure. After surgery, women received antibiotics on a case by 
case basis based on risk factors during surgery or post-operative risk assessment. Estrogen 
cream is typically not available in Malawi, but was used as needed post-operatively in post-
menopausal women, when available. Patients remained in the hospital ward with an 
indwelling catheter for a variable period of time at the discretion of the surgeon (typically 
10-21 days), based on the nature and difficulty of the surgical repair.
Women were included in the present analysis if they were diagnosed with vesicovaginal 
fistula, underwent their first repair surgery at the Fistula Care Center between September 
2011 and December 2014, completed a baseline survey, and returned for their first follow-up 
assessment within 120 days of their repair. Women who had undergone previous fistula 
repair surgeries at an outside facility were not excluded. Women who did not have a 
successful fistula closure, as determined by post-operative dye test (on average at 14 days 
post-operative), were also not excluded. However, women without fistula and those with 
non-vesicovaginal causes of fistula were excluded. Information on malignancies was not 
available in our data. Ethical approval was obtained from the National Health Sciences 
Research Committee of Malawi (Protocol #929) and the University of North Carolina 
School of Medicine Institutional Review Board (#11-2345). Women over 18 gave informed 
consent, while those under 18 underwent parental consent and pediatric assent. Trained 
research assistants double-entered and compared the data using REDCap (Research 
Electronic Data Capture, NC).(14)
The primary outcome was residual urinary incontinence, defined as incontinence grade 2-5 
irrespective of fistula closure status,(15) within 120 days of fistula repair surgery. Women 
were asked to return for follow-up within 30 days of discharge (typically 14-30 days after 
repair) to assess surgical outcomes. However, due to the rural nature of much of Malawi and 
the fact that the Fistula Care Center draws women from around the East Africa region, 
women included in this analysis were allowed up to 120 days from time of surgery to return 
for follow-up. We chose incontinence, rather than fistula closure, as our primary outcome 
since 20% (8) of women with a successful closure may remain incontinent.(5-7)
Both clinical and demographic predictors of residual incontinence within 120 days of 
surgery were considered. Candidate predictors were selected based on literature review and 
clinical consideration. However, we prioritized information likely to be readily available to 
physicians prior to performing a fistula surgery in settings like Malawi. We considered the 
following predictors: age as a proxy for menopausal status,(16, 17) number of years with 
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fistula,(16-18) HIV status,(19) body mass index, previous repair surgery at an outside 
facility,(8, 20) revised Goh Classification,(21) Goh vesicovaginal fistula size,(22) 
circumferential fistula,(8, 23) vaginal scaring,(8, 23) bladder size,(8, 17) and urethral length.
(8, 23)
In order to develop a risk score that could easily be calculated by hand by clinical staff 
working in resource-limited settings, all candidate predictors were coded as binary or 
categorical variables. Variables were categorized based on clinical considerations and to 
allow enough variation across the data (e.g. to avoid categories with a small number of 
observations).
The primary goal of our analysis was to develop an easy-to-use clinical tool to identify 
women with vesicovaginal fistula who are at high risk of residual urinary incontinence after 
surgical repair. The analysis comprised two steps. First, we developed a predictive model for 
residual urinary incontinence within 120 days of fistula repair surgery and used the beta 
coefficients from the model to develop a risk score. We then internally validated the risk 
score by bootstrapping.(24)
To develop the risk score, we used logistic regression to estimate unadjusted (bivariable) 
odds ratios (ORs) and 95% confidence intervals (CIs) for all candidate predictors. Predictors 
associated with residual incontinence within 120 days of surgery with a p-value ≤ 0.25 were 
identified and included in the full multivariable model. To reduce the full model to a more 
parsimonious final model we used manual backward elimination based on likelihood ratio 
tests. After the elimination of each variable, the area under the curve (AUC) was compared 
with the full model to determine whether the two models had comparable predictive ability. 
Multi-collinearity was assessed using Spearman correlations. For variables that were 
collinear, the variable with the strongest predictive power (e.g. largest coefficient) was 
retained in the final model. Variable elimination stopped when all predictors remaining in 
the multivariable model had at least one category with a p-value ≤ 0.10, in an effort to 
balance including potentially important predictors with parsimony. We used the Hosmer-
Lemeshow test to assess model fit and assessed outliers and influential observations using 
Pregibon leverage and deviance residuals.
To calculate the final risk score, beta coefficients from the final logistic regression model 
were multiplied by 10 and rounded to the nearest integer. The values associated with each 
person's covariates were summed to calculate a risk score for each person. Next, the 
sensitivity and specificity of each risk score cut-point to identify women with residual 
incontinence was assessed in the entire study population. Based on clinical considerations, a 
risk score cut-point with sensitivity > 80% and specificity >60% was specified as optimal a 
priori. We selected these thresholds for sensitivity and specificity in order to prioritize 
identifying the women with a high likelihood of residual incontinence (higher sensitivity), 
while preserving an acceptable ability to identify women likely to be continent after surgery 
(specificity).
We internally validated the risk score by bootstrapping the original data set (n=1,000) and 
comparing the distributions of sensitivity and specificity in the bootstrapped and observed 
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data.(24). All statistical analyses were performed using Stata version 13 (StataCorp, College 
Station, Texas).
Results
A total of 401 women who underwent a vesicovaginal fistula repair who returned to the 
Fistula Care Centre within 120 days of their surgery and had information on residual 
incontinence at that time were included in our analysis (Figure 1). Of 383 women with post-
operative dye tests, 372 (97%) were negative indicating successful fistula closure. Of those 
with successful fistula closure (n=372), 85 (23%) experienced residual incontinence. 
Overall, 97 (24%) women had residual urinary incontinence within 120 days of surgery. The 
majority of women (84%) were < 50 years of age, which was considered a proxy for being 
premenopausal. The prevalence of HIV was lower (7%) than reported for women in the 
general population in Malawi (13%).(25) A high proportion of women had been living with 
a fistula for 6 or more years (42%) or 0 to 5 years (45%). Nearly a quarter of patients (24%) 
had undergone a previous operation at an outside facility. Clinical characteristics indicating 
complicated fistulas were common: 26% of women had a fistula >3cm in size, 29% had 
circumferential fistula and 56% had vaginal scaring that was moderate to obliterated (Table 
1).
In the bivariable analysis, age, number of years with fistula, prior surgery at an outside 
facility, Goh vesicovaginal fistula size, circumferential fistula, vaginal scarring, bladder size, 
and urethral length were identified as predictors of residual urinary incontinence and 
included in the full multivariable model. Revised Goh classification was also predictive of 
residual incontinence, but due to limited sample size in some categories and strong 
collinearity with urethral length and circumferential fistula, it was not included in the full 
multivariable model. The final multivariable model included all from the full multivariable 
model, with the exception of number of years with a fistula and bladder size. These two 
variables were removed based on likelihood ratio tests (Table 2). The final multivariable 
model had good predictive ability, with an area under the curve of 0.82 (95% CI 0.77, 0.86).
The final multivariable model included 354 women with complete data. Individual risk 
scores ranged from 0 to 65. A risk score cut-point of >_20 had sensitivity 82% (95% CI 
72%, 89%) and specificity 63% (95% CI 57%, 69%) to identify women with residual 
urinary incontinence within 120 days of surgery and met our a priori criteria for satisfactory 
sensitivity (>80%) and specificity (>60%) (Figure 2). In our population, the overall 
prevalence of residual incontinence was 24%. This resulted in a positive predictive value for 
a risk score cut-point of 20 of 43% (95% CI 36%, 51%) and the negative predictive value of 
91% (95% CI 86%, 94%) (Figure 3). Using a risk score cut-point of 20 to identify women 
who may benefit from a more experienced surgeon or other additional intervention would 
identify 48% of the population for referral. A risk score cut-point of 20 identified 27% of the 
population who did not develop residual incontinence as high risk for residual incontinence, 
and did not identify 4% of the population who did develop residual incontinence (Appendix 
1, available online at http://links.lww.com/xxx). Bootstrapped values of sensitivity and 
specificity were very similar to those observed in the data, indicating good internal validity 
of the risk score.
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Discussion
Obstetric fistula remains one of the most debilitating conditions a woman can experience. 
Surgical repair remains the best hope for regaining urinary continence, but the need for 
greater agreement on prognostic factors for urinary incontinence has been discussed(11, 
26)). Our analysis attempts to address this issue by developing a risk score to identify 
women with vesicovaginal fistula who are at high risk of residual urinary incontinence 
within 120 days of repair based on a range of prognostic factors. In our setting, a risk score 
cut-point of ≥ 20 had satisfactory sensitivity and specificity, low positive predictive value 
and high negative predictive value to identify women with a high likelihood of residual 
incontinence. As with all risk scores, external validation of the risk score with an 
independent dataset is required before use in alternative settings.
Our risk score was developed using data from a referral fistula center in sub-Saharan Africa. 
Many of the women included in our analysis had complicated fistulas and surgical repair 
was performed by experienced surgeons. However, the decision about whether to refer 
women to more advanced surgeons typically takes place at district or community hospitals. 
Prior to surgery, physicians could easily calculate a risk score (see Appendix 2, available 
online at http://links.lww.com/xxx) for all patients based on their clinical characteristics. If 
validated in these alternative settings, the risk score may provide a useful diagnostic for 
distinguishing women most likely to benefit from specialized care and those likely to have 
good surgical outcome with lower-level fistula surgeons. Interventions such as pre and 
postoperative physical therapy and health education have been shown to reduce residual 
incontinence after surgery.(27) Preventative surgical measures, such as the pubococcygeal 
sling or traditional fascial sling, may also reduce the changes of residual incontinence after 
surgery.(13)
In our setting the negative predictive of using a risk score cut-point of ≥ 20 was 91%, 
indicating a high probability of continence after surgery for women with a risk score <20. 
However, because the prevalence of residual incontinence can vary widely by population, it 
is important to remember that the positive and negative predictive values of the risk score at 
any cut-point will vary based on the prevalence. In settings with less experienced surgeons, 
the prevalence of residual incontinence after surgery would be expected to be higher, and 
therefore the negative predictive value lower.
The overall prevalence of residual urinary incontinence within 120 days of repair surgery 
was 24% in our study population. This proportion is similar to what has been reported in 
other sub-Saharan African settings.(28) However, there is no agreed upon time after surgery 
for reporting the prevalence of residual incontinence and estimates vary widely by study, 
from 5% (9) to nearly 40%.(10) The somewhat higher prevalence of residual incontinence in 
our study likely reflects the fact that complicated cases or cases where previous surgery has 
failed (24% in our study population) are frequently referred to our center.
Our study had a number of important strengths. Our analysis draws on one of the largest 
databases of obstetric fistula patients in sub-Saharan Africa with a high proportion of post-
operative follow-up (75%) to develop a standardized clinical tool that may identify women 
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at high risk of residual incontinence after fistula repair surgery. Given our large and diverse 
population, we were able to evaluate a number of pre-operative characteristic as potential 
predictors of residual urinary incontinence in our analysis.
Our study also has important limitations. Data in our analysis come from a large fistula care 
referral center which draws patients, many with complicated fistula, from throughout the 
East Africa region. A majority of surgeries were performed by an experienced fistula 
surgeon with over 15 years of experience. Thus, our risk score may not be generalizable to 
clinics or health centers with less experienced surgeons, where the need to triage women 
based on their prognosis for surgical success may be greatest, and would need to be 
validated before use. Our risk score also may not be generalizable to resource-rich settings 
where the prevalence of vesicovaginal fistula is extremely low and fistulas that do occur are 
likely to be less complicated and not related to obstructed labor. Finally, even with our large 
sample of vesicovaginal fistula patients, we had to categorize some variables, such as 
urethral length and bladder size, more coarsely than would be clinically optimal due to 
limited sample size.
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Figure 1. 
Flowchart of study population of women with vesicovaginal and a measure of urinary 
incontinence within 120 days of fistula repair surgery.
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Figure 2. 
Sensitivity and specificity at each risk score cut-point. The reference line at 20 indicates the 
risk score cut-point with sensitivity of >80% and specificity >60%.
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Figure 3. 
Positive predictive value and negative predictive value for a risk score cut-point of 20, by 
prevalence. The reference line at 24% indicates the prevalence of residual incontinence in 
the study population.
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Table 1
Pre-operative characteristics of 401 undergoing vesicovaginal fistula repair, by incontinence status within 120 
days of surgery.
Pre-operative characteristic Continent
N=304 (75.8)
Residual Incontinence
N=97 (24.2) P-value
*
Age <0.01
    <50 266 (88.1) 67 (69.8)
    ≥50 36 (11.9) 29 (30.2)
        Missing, n 2 1
Number of years with fistula 0.01
    0-5 years 127 (49.0) 23 (29.9)
    6-20 years 104 (40.2) 38 (49.4)
    >20 years 28 (10.8) 16 (20.8)
        Missing, n 45 20
HIV status 0.56
    HIV − 280 (93.0) 90 (94.7)
    HIV + 21 (7.0) 5 (5.3)
        Missing, n 3 2
Body mass index, kg/m2 0.94
    < 25.0 217 (78.9) 69 (79.3)
    ≥ 25.0 58 (21.1) 18 (20.7)
        Missing, n 29 10
Number of prior fistula surgeries (at outside facility) 0.02
    0 240 (79.2) 65 (67.7)
    ≥ 1 63 (20.8) 31 (32.3)
        Missing, n 1 1
Revised Goh classification <0.01
    Type 1 138 (48.1) 7 (7.5)
    Type 2 66 (23.0) 21 (22.3)
    Type 3 66 (23.0) 45 (47.9)
    Type 4 17 (5.9) 21 (22.3)
        Missing, n 17 3
Goh vesicovaginal fistula size <0.01
    <1.5 cm 115 (40.2) 20 (21.3)
    1.5-3.0 cm 108 (37.8) 39 (41.5)
    >3.0 cm 63 (22.0) 35 (37.2)
        Missing, n 18 3
Circumferential fistula <0.01
    No 241 (29.3) 42 (43.3)
    Yes 63 (20.7) 55 (56.7)
        Missing, n 0 0
Vaginal scarring <0.01
    None/Mild 150 (51.2) 20 (20.6)
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Pre-operative characteristic Continent
N=304 (75.8)
Residual Incontinence
N=97 (24.2) P-value
*
    Moderate/Severe/Obliterated 143 (48.8) 77 (79.4)
        Missing, n 11 0
Bladder size, measured from urethra 0.02
    Large (>6 cm) 118 (43.7) 28 (29.8)
    Small/moderate (≤ 6 cm) 152 (56.3) 66 (70.2)
        Missing, n 34 3
Urethral length <0.01
    >1.5 cm 245 (89.4) 60 (62.5)
    ≤1.5 cm 29 (10.6) 36 (37.5)
        Missing, n 30 1
*
P-values based on chi-square tests.
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